C92.41

Clinical Causes: Genetic changes: A specific chromosomal abnormality known as t(15;17) translocation, which involves the PML and RARA genes, is a hallmark of APL. Age: The disease can occur at any age but is most common in adults aged 20-50. Exposure to radiation or chemotherapy: Prior exposure to high doses of radiation or certain chemotherapeutic agents may increase risk. Environmental factors: Some reports suggest that exposure to benzene and other chemicals could be linked to leukemia development. Family history: Although rare, having a family history of blood cancers might slightly raise risk.

Key Symptoms: Fatigue and weakness Unusual bleeding or bruising Frequent or severe infections Fever Petechiae (small red or purple spots on the skin) Shortness of breath Paleness Bleeding gums Unexplained weight loss Abdominal discomfort due to enlarged spleen or liver

Diagnosis Path: Blood tests: Complete blood count (CBC) often reveals abnormal levels of white blood cells, red blood cells, and platelets. Bone marrow biopsy: A sample of bone marrow is examined microscopically to identify abnormal promyelocytes. Cytogenetic analysis: Identifies the characteristic t(15;17) translocation. Molecular testing: Detects the PML-RARA fusion gene responsible for APL. Imaging studies: May be used to assess organ involvement or complications.

Treatment Protocols: All-trans retinoic acid (ATRA): A vitamin A derivative that promotes the maturation of abnormal promyelocytes into normal cells. Chemotherapy: Typically includes agents such as arsenic trioxide, idarubicin, or daunorubicin to eliminate leukemia cells. Supportive care: Includes blood transfusions, antibiotics to manage infections, and management of bleeding tendencies. Monitoring: Regular follow-up tests to ensure the disease remains in remission and to detect early signs of relapse.